Skip to main content
Premium Trial:

Request an Annual Quote

Pharsight Licenses Diabetes Meta-Database to Undisclosed Biotech

NEW YORK (GenomeWeb News) — Pharsight has licensed its public-source type II diabetes meta-database to an undisclosed biotechnology company, the informatics shop said today.
 
The deal is the firs time Pharsight has licensed one of its 20 meta-databases, which compare the “simulated” efficacy and safety of candidate drugs against those of existing drugs, the company said.
 
According to Pharsight, the drug maker plans to use the database to build quantitative models of the “competitive landscape” for oral diabetes treatments that will “help inform clinical program decision-making” for compounds.
 
In a statement, Pharsight said its diabetes meta-database comprises clinical efficacy and safety measures from 106 clinical trials, including multiple drug classes and comparative treatments, and more than 30 clinical endpoints.
 
Financial details of the deal were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.